Landmark New England Journal of Medicine Publication Reports Positive Results From PROMISE II Pivotal Trial Showing that LimFlow System Saves Most Patients with End-stage Peripheral Artery Disease From Major Amputation by Seini Moimoi | Mar 30, 2023 | Portfolio News
89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks by Seini Moimoi | Mar 22, 2023 | Portfolio News
Somatus Expands Partnership with Inova to Further Enhance Care and Improve Outcomes for Patients by Seini Moimoi | Mar 9, 2023 | Portfolio News
Avenge Bio Receives Positive Feedback from Pre-IND FDA Meeting on Development Path for AVB-001 Mesothelioma Program and Provides Pipeline Update by Seini Moimoi | Mar 9, 2023 | Portfolio News
Ceribell Named to Fast Company’s 2023 List of the World’s Most Innovative Companies by Seini Moimoi | Mar 2, 2023 | Portfolio News
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants by Seini Moimoi | Feb 21, 2023 | Portfolio News
Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 by Seini Moimoi | Feb 16, 2023 | Portfolio News
Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria by Seini Moimoi | Jan 30, 2023 | Portfolio News
Cohere Health Introduces Cohere Unify™ Intelligent Prior Authorization by Seini Moimoi | Jan 25, 2023 | Portfolio News
Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD) by Seini Moimoi | Jan 11, 2023 | Portfolio News
